Modelling long-term persistence of hepatitis B antibodies after vaccination

Journal of Medical Virology

Volumn 57, Issue 2, 1999, Pages 100-103

  Vellinga, A ^a   Van Damme, P ^a   Bruckers, L ^b   Weyler, J J ^a   Molenberghs, G ^b   Meheus, A ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

Author keywords

Hepatitis B; Linear mixed models; Long term; Mentally retarded

Indexed keywords

ANTICONVULSIVE AGENT; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; FEMALE; HUMAN; IMMUNOLOGICAL MEMORY; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; RISK FACTOR; VACCINATION;

ANTICONVULSANTS; DOWN SYNDROME; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; INSTITUTIONALIZATION; MALE; MENTAL RETARDATION; MODELS, IMMUNOLOGICAL; REGRESSION ANALYSIS; SEX FACTORS; TIME;

EID: 0032895613     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199902)57:2<100::AID-JMV2>3.0.CO;2-M     Document Type: Article

References (17)

1. Coursaget P, Yvonnet B, Gilks WR, Wang CC, Day NE, Chiron JP, Diop-Mar I. 1991. Scheduling of revaccination against hepatitis B virus [see comments]. Lancet 337:1180-1183.
2. Da Villa G, Peluso F, Picciotto L, Bencivenga M, Elia S, Pelliccia MG. 1996. Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life: follow-up at 5 and 10 years. Vaccine 14:1503-1505.
3. De Ponti F, Lecchini S, Cosentino M, Castelletti CM, Malesci A, Frigo GM. 1993. Immunological adverse effects of anticonvulsants. What is their clinical relevance? Drug Safety 8:235-250.
4. Gesemann M, Scheiermann N. 1995. Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence. Vaccine 13:443-447.
5. Gilks WR, Wang CC, Yvonnet B, Coursaget P. 1993. Random-effects models, for longitudinal data using Gibbs sampling. Biometrics 49:441-453.
6. Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF, Ostrow DG, O'Malley PM, Penley KA, Altman NL. 1986. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 315:209-214.
7. Hayashi J, Noguchi A, Nakashima K, Morofuji M, Kashiwagi S. 1991. Long term observation of the effect of intradermal hepatitis B vaccination on mentally retarded patients. Eur J Epidemiol 7:649-653.
8. Jilg W, Schmidt M, Deinhardt F, Zachoval R. 1984. Hepatitis B vaccination: how long does protection last? [letter]. Lancet 2:458.
9. Jilg W, Schmidt M, Deinhardt F. 1990. Decline of anti-HBs after hepatitis B vaccination and timing of revaccination [letter]. Lancet 335:173-174.
10. Nespoli L, Burgio GR, Ugazio AG, Maccario R. 1993. Immunologic features of Down's syndrome: a review. J Intellectual Dis Res 37: 543-551.
11. Nommensen FE, Go ST, MacLaren DM. 1989. Half-life of HBs antibody after hepatitis B vaccination: an aid to timing of booster vaccination [see comments]. Lancet 2:847-849.
12. Tabor E, Cairns J, Gerety RJ, Bayley AC. 1993. Nine-year follow-up study of a plasma-derived hepatitis B vaccine in a rural African setting. J of Med Virol 40:204-209.
13. Vellinga A, Van Damme P, Meheus A. Hepatitis B and C in institutions for the mentally retarded: a review. J Intellectual Dis Res (accepted, 1998)
14. Vellinga A, Van Damme P, Weyler JJ, Vraudex R, Meheus A. Hepatitis B vaccination in mentally retarded: effectiveness after 11 years. Vaccine (in press, 1999).
15. Verbeke G, Molenberghs G. 1997. Linear mixed models in practice: an SAS-orientated approach. Lecture notes in statistics, vol. 126. New York: Springer-Verlag.
16. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. 1997. Protection provided by hepatitis B vaccine in a Yupik Eskimo population - Results of a 10-year study. J Infect Dis 175:674-677.
17. West DJ, Calandra GB. 1996. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 14:1019-1027.